Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

HLS Therapeutics Inc (HLS) Stock Price & Analysis

49 Followers

HLS Stock Chart & Stats

CA$4.44CA$0.19(4.47%)
At close: 4:00 PM EST
C$3.75C$4C$4.25C$4.5Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
CAD 4.26 - CAD 4.50
52-Week Range
CAD 3.56 - CAD 5.44
Previous Close
CAD 4.25
Volume
N/A
Average Volume (3M)
78.12K
Market Cap
CAD 131.47M
Enterprise Value
CAD 177.89M
Total Cash (Recent Filing)
CAD 13.71M
Total Debt (Recent Filing)
CAD 41.84M
Price to Earnings (P/E)
―
Beta
0.66
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.09
Last Dividend Ex-Date
Apr 27, 2023
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Consistently positive operating and free cash flow gives HLS internal funding capacity while accounting earnings remain negative. This supports debt reduction, product investment, and operating resilience, making the business less dependent on external financing over the next several quarters.

Cardiovascular Portfolio Momentum

Rapid cardiovascular growth provides a durable expansion engine beyond the existing portfolio. Vascepa is delivering double-digit sales and unit growth, while Nilemdo is gaining prescriptions and payer access, creating a broader base for revenue and margin growth.

Improving Balance Sheet

Meaningful deleveraging improves financial flexibility and should reduce interest burdens, allowing more cash to support commercialization and growth. Lower debt also strengthens HLS's ability to manage product launches and absorb operating volatility over the medium term.

Bears Say

Persistent Accounting Losses

Persistent net losses and negative return on equity show that HLS has not yet converted its healthy EBITDA and cash generation into sustainable bottom-line profitability. This limits earnings quality and could constrain capital allocation if losses continue across coming reporting periods.

U.S. Clozaril Pressure

Declining U.S. Clozaril revenue and an expectation of flat sales indicate that an established product is unlikely to provide near-term growth support. Continued weakness places more importance on successful cardiovascular launches to offset pressure in the existing portfolio.

Margin Pressure From Launch Costs

Nilemdo commercialization is currently consuming investment before its revenue scale fully offsets higher expenses. The resulting EBITDA decline demonstrates near-term margin pressure, and sustained spending could delay the point at which portfolio growth translates into stronger overall profitability.

HLS Therapeutics Inc News

HLS FAQ

What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was C$3.56 and its highest was C$5.44 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
HLS Therapeutics Inc’s market cap is C$131.47M.
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 6 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -C$0.042 earnings per share for the quarter, beating the consensus estimate of -C$0.112 by C$0.07.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of ―. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 30,935,060 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -C$0.042 in its last earnings report, beating expectations of -C$0.112. Following the earnings report the stock price went up 3.916%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:HLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology